Future Directions in Osteoporosis Therapeutics

被引：27

作者：

Bone, Henry ^{[1
]}

机构：

[1] St John Hosp & Med Ctr, Michigan Bone & Mineral Clin, Sect Endocrinol & Metab, Detroit, MI 48236 USA

来源：

ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA | 2012年 / 41卷 / 03期

关键词：

Osteoporosis; Osteocytes; Antiresorptives; Anabolic agents; CATHEPSIN-K INHIBITOR; POSTMENOPAUSAL WOMEN; PARATHYROID-HORMONE; BONE MASS; AMERICAN-SOCIETY; TASK-FORCE; ESTROGEN; ALENDRONATE; PREVENTION; FRACTURES;

D O I：

10.1016/j.ecl.2012.05.003

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

Future directions in osteoporosis treatment will include development of medications with increasingly precise mechanistic targets, including the RANK-ligand pathway, cathepsin K inhibition, and Wnt signaling manipulation. More gains are likely with anabolics and newer antiresorptives that cause little or no suppression of formation. Optimal treatment of osteoporosis may require coordination of anabolic and antiresorptive treatment, following stimulation of bone formation with consolidation and long-term maintenance. Some well-established drugs may be useful in such regimens. We can also anticipate emphasis on cost containment using currently available drugs, especially as they become generic. Effective implementation and treatment continuity will be important themes.

引用

页码：655 / +

页数：8

共 31 条

[1]

Effects of conjugated, equine estrogen in postmenopausal women with hysterectomy - The women's health initiative randomized controlled trial [J].

Anderson, GL ;

Limacher, M ;

Assaf, AR ;

Bassford, T ;

Beresford, SAA ;

Black, H ;

Bonds, D ;

Brunner, R ;

Brzyski, R ;

Caan, B ;

Chlebowski, R ;

Curb, D ;

Gass, M ;

Hays, J ;

Heiss, G ;

Hendrix, S ;

Howard, BV ;

Hsia, J ;

Hubbell, A ;

Jackson, R ;

Johnson, KC ;

Judd, H ;

Kotchen, JM ;

Kuller, L ;

LaCroix, AZ ;

Lane, D ;

Langer, RD ;

Lasser, N ;

Lewis, CE ;

Manson, J ;

Margolis, K ;

Ockene, J ;

O'Sullivan, MJ ;

Phillips, L ;

Prentice, RL ;

Ritenbaugh, C ;

Robbins, J ;

Rossouw, JE ;

Sarto, G ;

Stefanick, ML ;

Van Horn, L ;

Wactawski-Wende, J ;

Wallace, R ;

Wassertheil-Smoller, S .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 291 (14) :1701-1712

[2]

The 2012 Hormone Therapy Position Statement of The North American Menopause Society [J].

不详 .

MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2012, 19 (03) :257-271

[3]

Binkley N, 2005, AM SOC BON MIN RES M

[4]

A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: The oral calcitonin in postmenopausal osteoporosis (ORACAL) trial [J].

Binkley, Neil ;

Bolognese, Michael ;

Sidorowicz-Bialynicka, Anna ;

Vally, Tasneem ;

Trout, Richard ;

Miller, Colin ;

Buben, Christine E. ;

Gilligan, James P. ;

Krause, David S. .

JOURNAL OF BONE AND MINERAL RESEARCH, 2012, 27 (08) :1821-1829

[5]

One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis [J].

Black, DM ;

Bilezikian, JP ;

Ensrud, KE ;

Greenspan, SL ;

Palermo, L ;

Hue, T ;

Lang, TF ;

McGowan, JA ;

Rosen, CJ .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (06) :555-565

[6]

Odanacatib, a Cathepsin-K Inhibitor for Osteoporosis: A Two-Year Study in Postmenopausal Women With Low Bone Density [J].

Bone, Henry G. ;

McClung, Michael R. ;

Roux, Christian ;

Recker, Robert R. ;

Eisman, John A. ;

Verbruggen, Nadia ;

Hustad, Carolyn M. ;

DaSilva, Carolyn ;

Santora, Arthur C. ;

Ince, B. Avery .

JOURNAL OF BONE AND MINERAL RESEARCH, 2010, 25 (05) :937-947

[7]

Alendronate and estrogen effects in postmenopausal women with low bone mineral density [J].

Bone, HG ;

Greenspan, SL ;

McKeever, C ;

Bell, N ;

Davidson, M ;

Downs, RW ;

Emkey, R ;

Meunier, PJ ;

Miller, SS ;

Mulloy, AL ;

Recker, RR ;

Weiss, SR ;

Heyden, N ;

Musliner, T ;

Suryawanshi, S ;

Yates, AJ ;

Lombardi, A .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (02) :720-726

[8]

The Amazing Osteocyte [J].

Bonewald, Lynda F. .

JOURNAL OF BONE AND MINERAL RESEARCH, 2011, 26 (02) :229-238

[9]

Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis [J].

Costa, Aline G. ;

Cusano, Natalie E. ;

Silva, Barbara C. ;

Cremers, Serge ;

Bilezikian, John P. .

NATURE REVIEWS RHEUMATOLOGY, 2011, 7 (08) :447-456

[10]

Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis [J].

Cummings, Steven R. ;

San Martin, Javier ;

McClung, Michael R. ;

Siris, Ethel S. ;

Eastell, Richard ;

Reid, Ian R. ;

Delmas, Pierre ;

Zoog, Holly B. ;

Austin, Matt ;

Wang, Andrea ;

Kutilek, Stepan ;

Adami, Silvano ;

Zanchetta, Jose ;

Libanati, Cesar ;

Siddhanti, Suresh ;

Christiansen, Claus .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (08) :756-765

← 1 2 3 4 →